A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients
- Conditions
- Herpes SimplexHIV Infections
- Registration Number
- NCT00002000
- Lead Sponsor
- Glaxo Wellcome
- Brief Summary
To evaluate the safety and efficacy of oral valacyclovir hydrochloride (256U87) vs. acyclovir in the treatment of recurrent anogenital herpes in HIV-infected patients (CD4 greater than or equal to 100).
- Detailed Description
Efficacy variables include the length of the episode, the time to lesion healing, the duration and severity of pain/discomfort, the duration of viral shedding, the proportion of patients with aborted episodes, the proportion of patients requiring extended therapy.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (22)
Univ of South Alabama
πΊπΈMobile, Alabama, United States
ViRx Inc
πΊπΈSan Francisco, California, United States
UCSF - San Francisco Gen Hosp
πΊπΈSan Francisco, California, United States
Denver Public Health Dept / Disease Control Services
πΊπΈDenver, Colorado, United States
West Haven Veterans Administration Med Ctr
πΊπΈWest Haven, Connecticut, United States
Univ of South Florida
πΊπΈTampa, Florida, United States
Emory Univ School of Medicine
πΊπΈAtlanta, Georgia, United States
Northwestern Memorial Hosp
πΊπΈChicago, Illinois, United States
Rush Presbyterian - Saint Luke's Med Ctr
πΊπΈChicago, Illinois, United States
Infectious Diseases Research Clinic / Indiana Univ Hosp
πΊπΈIndianapolis, Indiana, United States
Scroll for more (12 remaining)Univ of South AlabamaπΊπΈMobile, Alabama, United States